Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters

Saint Priest En Jarez, France Clinical Trials

A listing of Saint Priest En Jarez, France clinical trials actively recruiting patients volunteers.

RESULTS

Found (253) clinical trials

Study of Immunotherapy in Combination With Chemotherapy in HER2-negative Inflammatory Breast Cancer

Inflammatory breast cancer (IBC) is a rare and highly aggressive subtype of locally advanced breast cancer representing approximately 5% of all breast cancers that requires immediate aggressive treatment. Significant progress has been made in recent years using a combination of treatments, including neoadjuvant chemotherapy, surgery and radiation therapy. Accumulating data …

Phase

0.0 miles

Learn More »

Comparison of Intermittent Androgen Deprivation Therapy With or Without Irradiation Recovery in Prostate Cancer Patients

Screening procedures will be performed up to three months before starting IADT. After obtaining informed consent, patients will be randomly allocated to one of two groups: Experimental group: IADT + IG-IMRT Control group: IADT In both study arms, the first injection of IADT will be administered in hospital on the …

Phase N/A

0.0 miles

Learn More »

Physical Activity Experiment on Male Prostate Cancer Patients

The main objective of this project is to measure the adherence of prostate cancer patients to a physical activity program with a tracking of the motivation by a pair.

Phase N/A

0.0 miles

Learn More »

Prostate Cancer With OligometaSTatic Relapse: Combining Stereotactic Ablative Radiotherapy and Durvalumab (MEDI4736)

As in other solid tumours, increasing evidence indicates that patients diagnosed with a limited number of prostate cancer metastases, so-called oligometastases, have a better prognosis compared with patients with extensive metastatic disease. Survival of patients with three or fewer metastases was superior compared with patients with more than three lesions. …

Phase

0.0 miles

Learn More »

Phase II Study of Regorafenib as Maintenance Therapy

Patients will be randomized 1:1 using a centralized randomization software, assuring concealment, with a minimization program controlling for the following factors: Histological subgroups: leiomyosarcoma versus synovial sarcoma versus other histological subtype Response to doxorubicin-based chemotherapy: partial response versus stable disease Centers The treatment will be administrated as long as it …

Phase

0.0 miles

Learn More »

Atezolizumab in Elderly Patients With Advanced Non-Small-Cell Lung Cancer and Receiving Carboplatin Paclitaxel Chemotherapy

Non Small Cell Lung Cancer (NSCLC) remains the leading cause of death by cancer in the world. Because of the increase in lung cancer incidence with age and the increase of life expectancy, about half of the patients are patients aged 70 or older. Several clinical trials have shown the …

Phase

0.0 miles

Learn More »

A Study of the Effect and Safety of Sparsentan in the Treatment of Patients With IgA Nephropathy

This is a randomized, multicenter, double-blind, parallel-group, active-control study. Approximately 280 patients aged 18 years will be enrolled in the study globally. The investigational drug (sparsentan) is a dual acting angiotensin receptor blocker and endothelin receptor antagonist. The active control is irbesartan. The purpose of the study is to evaluate …

Phase

0.0 miles

Learn More »

Phase

0.0 miles

Learn More »

Safety and Efficacy of Ponatinib Followed by Imatinib in Patients With Chronic Myelogenous Leukemia in Chronic Phase

TREATMENT PLAN : All eligible patients will be treated: During the induction Phase (Month 1 to Month 6) with ponatinib (30mg/day) single agent; then During the consolidation Phase (Month 7 to Month 36) with imatinib (400mg/day) single agent; then From M36 : Patients with stable MR4.5 (i.e. since at least …

Phase

0.0 miles

Learn More »

Randomized Open Label Clinical Study of the Targeted Therapy Palbociclib to Treat Metastatic Breast Cancer

Subjects will be randomized into one of two treatment arms following minimum of 4 and maximum of 8 cycles of induction treatment with anti-HER2 therapy. Arm A subjects will receive the experimental therapy, palbociclib, in addition to their current anti-HER2 therapy and endocrine therapy. Arm B subjects will continue to …

Phase

0.0 miles

Learn More »